{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T03:05:19Z","timestamp":1789182319163,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Patient"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40271-025-00779-x","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T01:44:47Z","timestamp":1759974287000},"page":"231-244","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["PAIRED: Quantitative and Qualitative PAtIent-Reported Experiences and perceiveD Benefit of Treatment with Dolutegravir\/Lamivudine in the United States"],"prefix":"10.1007","volume":"19","author":[{"given":"Jihad","family":"Slim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Brogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Harper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Mycock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"McMillan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanna","family":"Merrill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Verdier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"issue":"5","key":"779_CR1","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.1016\/S2352-3018(23)00028-0","volume":"10","author":"A Trickey","year":"2023","unstructured":"Trickey A, Sabin CA, Burkholder G, et al. Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies. Lancet HIV. 2023;10(5):e295-307.","journal-title":"Lancet HIV."},{"key":"779_CR2","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services; 2024. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv. Accessed 14 Apr 2025."},{"issue":"4","key":"779_CR3","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1093\/cid\/ciac130","volume":"76","author":"JM Llibre","year":"2022","unstructured":"Llibre JM, Brites C, Cheng C-Y, et al. Efficacy and safety of switching to the 2-drug regimen dolutegravir\/lamivudine versus continuing a 3- or 4-drug regimen for maintaining virologic suppression in adults living with human immunodeficiency virus 1 (HIV-1): week 48 results from the phase 3, noninferiority SALSA randomized trial. Clin Infect Dis. 2022;76(4):720\u20139.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"779_CR4","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1093\/cid\/ciac036","volume":"75","author":"O Osiyemi","year":"2022","unstructured":"Osiyemi O, De Wit S, Ajana F, et al. Efficacy and safety of switching to dolutegravir\/lamivudine versus continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: results through week 144 from the phase 3, noninferiority TANGO randomized trial. Clin Infect Dis. 2022;75(6):975\u201386.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"779_CR5","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1097\/QAI.0000000000003395","volume":"96","author":"S De Wit","year":"2024","unstructured":"De Wit S, Bonnet F, Osiyemi O, et al. Durable efficacy of switching from a 3- or 4-drug tenofovir alafenamide-based regimen to the 2-drug regimen dolutegravir\/lamivudine in the TANGO study through week 196. J Acquir Immune Defic Syndr. 2024;96(2):156\u201360.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"779_CR6","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/j.1524-4733.2006.00121.x","volume":"9","author":"A Woodcock","year":"2006","unstructured":"Woodcock A, Bradley C. Validation of the revised 10-item HIV treatment satisfaction questionnaire status version and new change version. Value Health. 2006;9(5):320\u201333.","journal-title":"Value Health"},{"key":"779_CR7","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.2147\/PPA.S358046","volume":"16","author":"S Bentley","year":"2022","unstructured":"Bentley S, Morgan L, Exall E, et al. Qualitative interviews to support development and cognitive debriefing of the Adelphi Adherence Questionnaire (ADAQ\u00a9): a patient-reported measure of medication adherence developed for use in a range of diseases, treatment modalities, and countries. Patient Prefer Adherence. 2022;16:2579\u201392.","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"779_CR8","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1186\/s12889-018-5433-6","volume":"18","author":"G Brown","year":"2018","unstructured":"Brown G, Miko\u0142ajczak G, Lyons A, et al. Development and validation of PozQoL: a scale to assess quality of life of PLHIV. BMC Public Health. 2018;18(1):527.","journal-title":"BMC Public Health"},{"issue":"2","key":"779_CR9","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77\u2013101.","journal-title":"Qual Res Psychol"},{"issue":"1","key":"779_CR10","volume":"9","author":"CJ Fearnley","year":"2022","unstructured":"Fearnley CJ. Mind mapping in qualitative data analysis: managing interview data in interdisciplinary and multi-sited research projects. Geo: Geography and Environment. 2022;9(1):e00109.","journal-title":"Geo: Geography and Environment"},{"key":"779_CR11","unstructured":"Australian Research Centre in Sex, Health and Society. PozQoL scale implementation kit version 2.0. Melbourne: La Trobe University; 2020. https:\/\/www.pozqol.org\/wp-content\/uploads\/PozQoL-Implementation-Kit.pdf. Accessed 14 Apr 2025."},{"issue":"2","key":"779_CR12","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/COH.0000000000000608","volume":"15","author":"EJ Edelman","year":"2020","unstructured":"Edelman EJ, Rentsch CT, Justice AC. Polypharmacy in HIV: recent insights and future directions. Curr Opin HIV AIDS. 2020;15(2):126\u201333.","journal-title":"Curr Opin HIV AIDS"},{"issue":"12","key":"779_CR13","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1080\/09540121.2024.2391439","volume":"36","author":"BK Tadese","year":"2024","unstructured":"Tadese BK, Hennessy F, Salmon P, Holbrook T, Prajapati G. Adherence to antiretroviral therapy and its association with quality of life among people with HIV in the United States. AIDS Care. 2024;36(12):1869\u201381.","journal-title":"AIDS Care"},{"issue":"9","key":"779_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26006","volume":"25","author":"CP Garris","year":"2022","unstructured":"Garris CP, Czarnogorski M, Dalessandro M, et al. Perspectives of people living with HIV-1 on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation-effectiveness study. J Int AIDS Soc. 2022;25(9):e26006.","journal-title":"J Int AIDS Soc"},{"issue":"2","key":"779_CR15","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/S2055-6640(20)30019-4","volume":"6","author":"T Pepperrell","year":"2020","unstructured":"Pepperrell T, Hill A, Moorhouse M, et al. Phase 3 trials of new antiretrovirals are not representative of the global HIV epidemic. J Virus Erad. 2020;6(2):70\u20133.","journal-title":"J Virus Erad"},{"issue":"1","key":"779_CR16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1089\/aid.2014.0205","volume":"31","author":"RE Johnston","year":"2015","unstructured":"Johnston RE, Heitzeg MM. Sex, age, race and intervention type in clinical studies of HIV cure: a systematic review. AIDS Res Hum Retroviruses. 2015;31(1):85\u201397.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"779_CR17","unstructured":"Centers for Disease Control and Prevention. Estimated HIV incidence and prevalence in the United States, 2018\u20132022. In: HIV Surveillance Supplemental Report 2024;29 (No. 1). 2024. https:\/\/www.cdc.gov\/hiv-data\/nhss\/estimated-hiv-incidence-and-prevalence.html. Accessed 14 Apr 2025."},{"issue":"1","key":"779_CR18","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/hiv.12280","volume":"17","author":"JL Casado","year":"2016","unstructured":"Casado JL, Mar\u00edn A, Romero V, et al. The influence of patient beliefs and treatment satisfaction on the discontinuation of current first-line antiretroviral regimens. HIV Med. 2016;17(1):46\u201355.","journal-title":"HIV Med"},{"issue":"1","key":"779_CR19","doi-asserted-by":"publisher","DOI":"10.2196\/13029","volume":"9","author":"K Volpicelli Leonard","year":"2020","unstructured":"Volpicelli Leonard K, Robertson C, Bhowmick A, Herbert LB. Perceived treatment satisfaction and effectiveness facilitators among patients with chronic health conditions: a self-reported survey. Interact J Med Res. 2020;9(1):e13029.","journal-title":"Interact J Med Res"},{"issue":"4","key":"779_CR20","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40121-024-00961-y","volume":"13","author":"S Schneider","year":"2024","unstructured":"Schneider S, Blick G, Burke C, et al. Two-drug regimens dolutegravir\/lamivudine and dolutegravir\/rilpivirine are effective with few discontinuations in US real-world settings: results from the tandem study. Infect Dis Ther. 2024;13(4):891\u2013906.","journal-title":"Infect Dis Ther"},{"issue":"3","key":"779_CR21","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1080\/0142159X.2022.2057287","volume":"45","author":"FM Olmos-Vega","year":"2022","unstructured":"Olmos-Vega FM, Stalmeijer RE, Varpio L, Kahlke R. A practical guide to reflexivity in qualitative research: AMEE guide no. 149. Med Teach. 2022;45(3):241\u201351.","journal-title":"Med Teach"},{"issue":"1","key":"779_CR22","first-page":"26","volume":"44","author":"NA Stahl","year":"2020","unstructured":"Stahl NA, King JR. Expanding approaches for research: understanding and using trustworthiness in qualitative research. J Dev Educ. 2020;44(1):26\u20139.","journal-title":"J Dev Educ"}],"container-title":["The Patient - Patient-Centered Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-025-00779-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40271-025-00779-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-025-00779-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T10:11:30Z","timestamp":1772014290000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40271-025-00779-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["779"],"URL":"https:\/\/doi.org\/10.1007\/s40271-025-00779-x","relation":{},"ISSN":["1178-1653","1178-1661"],"issn-type":[{"value":"1178-1653","type":"print"},{"value":"1178-1661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,9]]},"assertion":[{"value":"1 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JS has served as the principal investigator for clinical trials for which his institution received grants and has received honoraria from AbbVie, Gilead, Janssen, Merck, Theratechnologies, and ViiV Healthcare. APB and DM are employees of ViiV Healthcare and own stock in GSK. GH, KM, and AM are employees of Adelphi Real World, which was contracted by ViiV Healthcare for this analysis. GV is an employee of ViiV Healthcare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Ethics approval to conduct this study was granted by Western Institutional Review Board (tracking reference, 20224682).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All participants provided informed consent to participate in surveys and interviews.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"All participants provided signed consent to publish anonymized findings before surveys and interviews were conducted.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Anonymized individual participant data and study documents can be requested for further research from\n                      \n                      .","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"GH, KM, AM, DM, and GV contributed to the conception of the study. APB, GH, KM, AM, DM, and GV contributed to the design of the study. JS, GH, KM, AM, and DM contributed to the acquisition of data. APB, GH, KM, AM, DM, and GV contributed to the analysis of data. All authors contributed to the interpretation of data, drafting the manuscript, and critically revising the manuscript for important intellectual content. All authors approved the manuscript for publication.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}